Mithra Announces Positive Outcome of Myring™ Commercial Batch Bioequivalence Study

  • Bioequivalence study performed on commercial Myring™ batch produced at Mithra CDMO
  • Data will form part of planned Myring™ FDA filing by US partner Mayne Pharma

Liège, Belgium, 17 November 2017 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, announces the successful outcome of a confirmatory bioequivalence study performed on a commercial batch of Myring™ produced at the Mithra CDMO. The study results reconfirm that Myring™ is bioequivalent to Nuvaring®, a combined hormonal contraceptive vaginal ring made of ethylene vinyl acetate copolymers (EVA).